FLT3 and acute myeloid leukemia: Midostaurin, gilteritinib, crenolanib, and sorafenib all had less inhibitory activity on the 3 FLT3-ITD cell lines than both quizartinib and AC886, suggesting that quizartinib and AC886 exert potent antileukemic activity selectively on FLT3-ITD AML (Figure 2D; Supplementary Table 3; Supplementary Figure 1).